SIRT1

Across TCGA pan-cancer cohorts, SIRT1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of SIRT1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SIRT1 RNA is repressed in tumor relative to normal tissue. In most cancer types SIRT1 is over-expressed in tumor, although a few such as BLCA and THCA show the opposite, repressed pattern.

BLCA, THCA, and KICH are the cancer types where SIRT1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SIRT1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	All	−0.814	<.001	10	view →
THCA	All	II,III,IV	−0.610	<.001	8	view →
KICH	Female	All	−1.267	<.001	7	view →
LUSC	Female	II,III,IV	−0.977	<.001	7	view →
BRCA	Female	All	−0.295	<.001	4	view →
CHOL	All	All	+0.864	.007	2	view →
READ	Female	All	−0.830	.012	2	view →
UCEC	All	All	−0.745	.001	2	view →
LUAD	Female	II,III,IV	−0.426	.011	2	view →
KIRC	All	All	+0.286	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

SIRT1–BLCA

Open the BLCA breakdown →